MRMD (MariMed) LT-Debt-to-Total-Asset: 0.42 (As of Mar. 2026)


What is MariMed LT-Debt-to-Total-Asset?

MariMed MRMD -2.21% LT-Debt-to-Total-Asset is 0.42 as of Mar. 2026. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. MariMed's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.42.

MariMed's long-term debt to total assets ratio increased from Mar. 2025 (0.38) to Mar. 2026 (0.42). It may suggest that MariMed is progressively becoming more dependent on debt to grow their business.

MariMed  (OTCPK:MRMD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

MariMed LT-Debt-to-Total-Asset Related Terms

MariMed LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for MariMed's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MariMed LT-Debt-to-Total-Asset Chart

MariMed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.20 0.39 0.38 0.39

MariMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.39 0.39 0.39 0.42

MariMed LT-Debt-to-Total-Asset Calculation

MariMed's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=78.764/202.565
=0.39

MariMed's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=83.98/201.185
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.42 mean?
MariMed (MRMD) has a LT-Debt-to-Total-Asset of 0.42 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on MariMed and its competitors.
Is MariMed's LT-Debt-to-Total-Asset too high?
MariMed's current LT-Debt-to-Total-Asset is 0.42.
How does MariMed's LT-Debt-to-Total-Asset compare to RMTI and CPHI?
MariMed's LT-Debt-to-Total-Asset of 0.42 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on MariMed and its competitors. MariMed's current LT-Debt-to-Total-Asset is 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.16, compared to a current price of $0.07 — trading 57.2% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.42. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For MariMed (MRMD), the current LT-Debt-to-Total-Asset is 0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MariMed Business Description

Other Exchanges MRMD:Canada
Address 10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.